by Product (Structural Proteins, Membrane Proteins, Chemokines and Growth Factors, and Others); by Application (Drug discovery & Development, Academic Research, and Others); by End User (Biotechnology Companies, CROs, and Others) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033
Buy Now
The global recombinant proteins market is projected to garner a revenue of ~USD 4 Billion by the end of 2033 by growing at a CAGR of ~11% over the forecast period, i.e., 2023-2033. Further, the market generated a revenue of ~USD 2 Billion in the year 2022. The recombinant market is expanding as a result of the rising frequency of chronic disorders such as granulomatous diseases, hemophilia, and sclerosis. These diseases are marked by persistent tissue damage and inflammation, and they frequently need continuing care. Targeting certain disease-causing proteins or cells using recombinant treatments, created utilizing methods of genetic engineering can increase the efficacy of treatment. For instance, mutations in any one of the NADPH oxidases in phagocytic leucocytes result in chronic granulomatous disease (CGD), a condition that affects only around 1 in 250,000 people globally.
During the early stages, recombinant technology was very important, as a result, numerous COVID-19 vaccines based on recombinant proteins were created with authorization for emergency use. For instance, the World Health Organization (WHO) published a 9th COVID-19 vaccine for Emergency Use Listing (EUL) for NVX-CoV2373 in December 2021. In low and middle-income nations such as Ukraine, Iran, South Africa, and other nations, vaccine access was made possible with the help of this EUL. The Covovax vaccine which is based on recombinant proteins and was developed by the Serum Institute of India (SII) was similarly approved by the Drugs Control General of India (DCGI) in December 2021 for kids from 7 to 12 years.
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~11% |
|
Base Year Market Size (2022) |
~ USD 2 Billion |
|
Forecast Year Market Size (2033) |
~ USD 4 Billion |
|
Regional Scope |
|
Growth Drivers
Increasing demand for recombinant protein drugs for rare diseases – Rare diseases are afflictions that affect very few people all around the world. The research and funding for the treatment of rare diseases are low and hence pose a problem to the people suffering from them. The growing prevalence of diseases such as multiple sclerosis (MS), neutropenia, cerebral apoplexy, anemia, and others as well as dwarfism is increasing the demand for recombinant protein medications. For instance, MS affects more than 2.9 million people worldwide.
Growing Health Expenditure on R&D – Research and development are key factors in driving wider acceptance and global usage of recombinant proteins. Better medical products can be created from recombinant proteins by increasing the expenditure of research and development for faster and more effective progress. For instance, global spending on research and development was predicted to increase from about USD 2.45 trillion in 2021 to around USD 2.5 trillion in 2022 around the globe.
Surge in Prevalence of Chronic Diseases – Diseases that are often lifelong or long-term are called chronic diseases. Chronic diseases often demand ongoing, consistent treatment. Recombinant proteins offer hope for patients by delivering effective results in chronic disease management. It is estimated that around 60% of American adults suffer from at least one chronic illness.
Rising Incidence of Hemophilia – A genetic bleeding ailment called hemophilia causes the blood to clot improperly. This may result in both spontaneous bleeding and bleeding after injury or surgery. Even though hemophilia in some situations can be life-threatening, it is however still classified as a rare disease. It is estimated that 1 in every 5000 male babies is born with hemophilia. In the United States alone, 400 newborns are diagnosed with hemophilia A per year.
Challenges
The global recombinant proteins market is segmented and analyzed for demand and supply by-products into structural proteins, membrane proteins, chemokines, and growth factors. The chemokines and growth factors are anticipated to hold the highest market share by the end of 2033. A significant component of the growth factors and chemokines market is attributed to the use of these molecules in numerous research fields including chemotaxis, neurobiology, wound healing, immunology, transplantation, apoptosis, cancer, HIV, COVID-19, cell culture, and stem cell research. According to the Centers for Disease Control and Prevention (CDC), around 1.2 million Americans suffer from HIV as of 2019 and the U.S. was responsible for over half (53%) of all new HIV infections in 2019.
The global recombinant proteins market is also segmented and analyzed for demand and supply by application into drug discovery & development, academic research, and others. Out of these segments, the drug discovery and development segment is projected to have the highest market share among all other segments. This can be owed to the fact that over the past years, both R&D spending and the release of new medications have surged. The pharmaceutical sector invested over USD 80 billion in research and development in 2019. This is more than a 1000% increase in research spending and drug discoveries when compared to the data of the previous decades.
The global recombinant proteins market is also segmented and analyzed for demand and supply by application into drug discovery & development, academic research, and others. Out of these segments, the drug discovery and development segment is projected to have the highest market share among all other segments. This can be owed to the fact that over the past years, both R&D spending and the release of new medications have surged. The pharmaceutical sector invested over USD 80 billion in research and development in 2019.This is more than a 1000% increase in research spending and drug discoveries when compared to the data of the previous decades. Besides this, the surging adoption of recombinant protein in the formation of regenerative medicine is also a major factor that is projected to drive segment growth in the coming years.
Our in-depth analysis of the global recombinant proteins market includes the following segments:
|
By Application |
|
|
By Product |
|
|
By End User |
|
The North American recombinant proteins market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033, owing to increased R&D spending, expanded research activities, and the rising frequency of chronic and contagious diseases, especially cancer. The overall number of cancer fatalities is still rising as a result of advancements made in the field of healthcare and medicine, since they offer rising life expectancy and population growth, particularly in high-income nations such as America. In the U.S., it was predicted be around 1,735,350 new cancer diagnoses and 609,640 cancer deaths in 2018.
Thermo Fisher Scientific, Inc.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Ans: Rising Prevalence of chronic diseases, increasing spending on research and development, and growing cases of rare diseases, also including hemophilia are some of the major factors driving the market growth.
Ans: The market is anticipated to attain a CAGR of ~11% over the forecast period, i.e., 2023 – 2033.
Ans: Low awareness about recombinant proteins and the possibility of side effects are some challenges affecting the market growth.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.
Ans: The major players in the market are Thermo Fisher Scientific, Inc., Bristol-Myers Squibb Company, Merck KGaA, Proteintech Group, Inc., Janssen-Cilag Pty Ltd., Aviva Systems Corporation, Bio-Techne Corporation, Elpiscience BioPharma, Eli Lilly and co., GigaGen Inc., and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by product, application, end-user, and by region.
Ans: The drug discovery factors are anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
